ALX Oncology Holdings Inc (ALXO) stock
ALXONasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.97−0.03 (-3.47%)
Close on Nov 18, 2026Market cap $134.14MP/E –Yield –
ALX Oncology operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
ALX Oncology's operating cash flow for the twelve months ending Jun 30, 2026 was -$70.78M. For fiscal 2025 it was -$84.14M. The highest annual figure on record is -$13.19M in fiscal 2018.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$84.14M | – |
| FY2024 | Dec 31, 2024 | -$121.91M | – |
| FY2023 | Dec 31, 2023 | -$130.36M | – |
| FY2022 | Dec 31, 2022 | -$89.22M | – |
| FY2021 | Dec 31, 2021 | -$68.10M | – |
| FY2020 | Dec 31, 2020 | -$38.29M | – |
| FY2019 | Dec 31, 2019 | -$14.25M | – |
| FY2018 | Dec 31, 2018 | -$13.19M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$16.06M | – |
| Q1 FY2026 | Mar 31, 2026 | -$18.65M | – |
| Q4 FY2025 | Dec 31, 2025 | -$18.98M | – |
| Q3 FY2025 | Sep 30, 2025 | -$17.09M | – |
| Q2 FY2025 | Jun 30, 2025 | -$23.41M | – |
| Q1 FY2025 | Mar 31, 2025 | -$24.66M | – |
| Q4 FY2024 | Dec 31, 2024 | -$32.05M | – |
| Q3 FY2024 | Sep 30, 2024 | -$25.38M | – |
| Q2 FY2024 | Jun 30, 2024 | -$26.57M | – |
| Q1 FY2024 | Mar 31, 2024 | -$37.92M | – |
| Q4 FY2023 | Dec 31, 2023 | -$39.68M | – |
| Q3 FY2023 | Sep 30, 2023 | -$31.16M | – |
| Q2 FY2023 | Jun 30, 2023 | -$31.71M | – |
| Q1 FY2023 | Mar 31, 2023 | -$27.82M | – |
| Q4 FY2022 | Dec 31, 2022 | -$20.67M | – |
| Q3 FY2022 | Sep 30, 2022 | -$30.88M | – |
| Q2 FY2022 | Jun 30, 2022 | -$17.00M | – |
| Q1 FY2022 | Mar 31, 2022 | -$20.67M | – |
| Q4 FY2021 | Dec 31, 2021 | -$17.49M | – |
| Q3 FY2021 | Sep 30, 2021 | -$24.86M | – |
| Q2 FY2021 | Jun 30, 2021 | -$20.62M | – |
| Q1 FY2021 | Mar 31, 2021 | -$5.14M | – |
| Q4 FY2020 | Dec 31, 2020 | -$13.62M | – |
| Q3 FY2020 | Sep 30, 2020 | -$9.55M | – |
| Q2 FY2020 | Jun 30, 2020 | -$6.16M | – |
| Q1 FY2020 | Mar 31, 2020 | -$8.96M | – |
| Q4 FY2019 | Dec 31, 2019 | -$2.87M | – |
| Q3 FY2019 | Sep 30, 2019 | -$3.19M | – |
See a number that looks wrong?